High Levels of Serum Dihomo-γ-linolenic Acid Are Associated with Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients

Overview

Journal Diabetol Int

Date 2025 Jan 29

PMID 39877445

Authors

Kohei Mochizuki

Mariko Higa

Kayoko Ikehara

Takamasa Ichijo

Takahisa Hirose

Affiliations

Soon will be listed here.

Abstract

An elevated level of saturated fatty acids (SFAs) can cause non-alcoholic fatty liver disease (NAFLD). While n-3 polyunsaturated fatty acids (PUFAs) were shown to improve NAFLD, the effects of n-6 PUFAs in the liver have not been fully elucidated. We examined the association between NAFLD and n-6 PUFAs, particularly dihomo-γ-linolenic acid (DGLA), in patients with type 2 diabetes. A total of 60 patients with type 2 diabetes were included in the study. Patients were categorized into the NAFLD group ( = 35) and non-NAFLD group ( = 25) based on the presence of fatty liver as determined by abdominal ultrasound. We demonstrated that the levels of serum SFAs, specifically palmitic acid and stearic acid, and the levels of n-6 PUFAs, specifically DGLA, and arachidonic acid (AA), were significantly higher in the NAFLD group. The serum palmitic acid, stearic acid, DGLA and AA levels were positively correlated with liver enzyme gamma-glutamyl transpeptidase (GGT). We further demonstrated by multivariate analysis that serum DGLA was a predictor of NAFLD. The serum DGLA level was negatively correlated with blood adiponectin and was positively correlated with blood leptin, high-sensitivity CRP, C-peptide index, and triglyceride-glucose index. Furthermore, delta-5-desaturase (D5D), the AA (product)/DGLA (precursor) ratio calculated from the product-to-precursor ratio of fatty acids, was significantly lower in the NAFLD group. These findings suggest that high serum DGLA levels in NAFLD group may be due to an excessive intake of n-6 PUFAs and changes in desaturase in the human body. High serum DGLA levels may also be associated with insulin resistance and inflammatory factors.

References

Gallagher H, Williams J, Ferekidis N, Ismail A, Chan Y, Michael D . Dihomo-γ-linolenic acid inhibits several key cellular processes associated with atherosclerosis. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9):2538-2550. PMC: 6620504. DOI: 10.1016/j.bbadis.2019.06.011. View

Ailhaud G, Guesnet P . Fatty acid composition of fats is an early determinant of childhood obesity: a short review and an opinion. Obes Rev. 2004; 5(1):21-6. DOI: 10.1111/j.1467-789x.2004.00121.x. View

Wu J, Marklund M, Imamura F, Tintle N, Ardisson Korat A, de Goede J . Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. Lancet Diabetes Endocrinol. 2017; 5(12):965-974. PMC: 6029721. DOI: 10.1016/S2213-8587(17)30307-8. View

Chan W, Chuah K, Rajaram R, Lim L, Ratnasingam J, Vethakkan S . Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023; 32(3):197-213. PMC: 10583766. DOI: 10.7570/jomes23052. View

Ricchi M, Odoardi M, Carulli L, Anzivino C, Ballestri S, Pinetti A . Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol. 2009; 24(5):830-40. DOI: 10.1111/j.1440-1746.2008.05733.x. View

Romero-Gomez M, Zelber-Sagi S, Trenell M . Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017; 67(4):829-846. DOI: 10.1016/j.jhep.2017.05.016. View

Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y . Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel). 2021; 11(1). PMC: 7830542. DOI: 10.3390/diagnostics11010132. View

Yang J, Fernandez-Galilea M, Martinez-Fernandez L, Gonzalez-Muniesa P, Perez-Chavez A, Martinez J . Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. Nutrients. 2019; 11(4). PMC: 6521137. DOI: 10.3390/nu11040872. View

Svendsen K, Olsen T, Nordstrand Rusvik T, Ulven S, Holven K, Retterstol K . Fatty acid profile and estimated desaturase activities in whole blood are associated with metabolic health. Lipids Health Dis. 2020; 19(1):102. PMC: 7243306. DOI: 10.1186/s12944-020-01282-y. View

10.

Kawashima A, Sugawara S, Okita M, Akahane T, Fukui K, Hashiuchi M . Plasma fatty acid composition, estimated desaturase activities, and intakes of energy and nutrient in Japanese men with abdominal obesity or metabolic syndrome. J Nutr Sci Vitaminol (Tokyo). 2009; 55(5):400-6. DOI: 10.3177/jnsv.55.400. View

11.

Tsurutani Y, Inoue K, Sugisawa C, Saito J, Omura M, Nishikawa T . Increased Serum Dihomo-γ-linolenic Acid Levels Are Associated with Obesity, Body Fat Accumulation, and Insulin Resistance in Japanese Patients with Type 2 Diabetes. Intern Med. 2018; 57(20):2929-2935. PMC: 6232036. DOI: 10.2169/internalmedicine.0816-18. View

12.

Ni Y, Zhao L, Yu H, Ma X, Bao Y, Rajani C . Circulating Unsaturated Fatty Acids Delineate the Metabolic Status of Obese Individuals. EBioMedicine. 2015; 2(10):1513-22. PMC: 4634820. DOI: 10.1016/j.ebiom.2015.09.004. View

13.

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

14.

Younossi Z, Golabi P, de Avila L, Paik J, Srishord M, Fukui N . The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019; 71(4):793-801. DOI: 10.1016/j.jhep.2019.06.021. View

15.

Rogero M, Calder P . Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids. Nutrients. 2018; 10(4). PMC: 5946217. DOI: 10.3390/nu10040432. View

16.

Capanni M, Calella F, Biagini M, Genise S, Raimondi L, Bedogni G . Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006; 23(8):1143-51. DOI: 10.1111/j.1365-2036.2006.02885.x. View

17.

Naughton S, Mathai M, Hryciw D, McAinch A . Linoleic acid and the pathogenesis of obesity. Prostaglandins Other Lipid Mediat. 2016; 125:90-9. DOI: 10.1016/j.prostaglandins.2016.06.003. View

18.

Lee C, Sharp S, Wexler D, Adler A . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial. Diabetes Care. 2010; 33(7):1454-6. PMC: 2890339. DOI: 10.2337/dc09-2245. View

19.

Argo C, Patrie J, Lackner C, Henry T, de Lange E, Weltman A . Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2014; 62(1):190-7. PMC: 4272639. DOI: 10.1016/j.jhep.2014.08.036. View

20.

Estevez-Vazquez O, Benede-Ubieto R, Guo F, Gomez-Santos B, Aspichueta P, Reissing J . Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). Biomedicines. 2021; 9(10). PMC: 8533605. DOI: 10.3390/biomedicines9101289. View